NEW YORK (GenomeWeb News) – Foundation Medicine reported after the close of the market Tuesday that its fourth quarter revenues climbed 87 percent year over year and 18 percent over the previous quarter.

The Cambridge, Mass.-based cancer genomic analysis firm reported total revenues of $9.7 million for the three months ended Dec. 31, up from $5.2 million in Q4 2012 and $8.2 million in Q3 2013. It beat the consensus Wall Street estimate of $9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.